The role of hematopoietic stem cells in the treatment of ovarian cancer

Panminerva Medica

Volumn 44, Issue 3, 2002, Pages 197-204

  Perillo, A ^a   Pierelli, L ^a   Scambia, G ^a   Leone, G ^a   Mancuso, S ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Hematopoietic stem cell transplantation; Ovarian neoplasms, immunology; Ovarian neoplasms, therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE;

ALLOTRANSPLANTATION; ANIMAL; FEMALE; GENE THERAPY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MULTIMODALITY CANCER THERAPY; OVARY TUMOR; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CYTOKINES; FEMALE; GENE THERAPY; GRAFT VS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; OVARIAN NEOPLASMS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0036719349     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Bathia M, Bonnet D, Murdoch B, Gan OI, Dick JE. A newly discovered class of human hemopoietic cells with SCID-repopulating activity. Nat Med 1998;9:1038-45.
2. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1999;49:8.
3. Hanai A. Trends and differentials in ovarian cancer: incidence, mortality and survival experience. APMIS (Suppl) 1990;12:1-20.
4. Brun JL, Feyler A, Chene G, Saurel J, Brun G, Hocke C. Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol 2000;78:21-7.
5. Skipper HE. Dose intensity versus total dose of chemotherapy: an experimental basis. In: De Vita V, Hellman S, Rosemberg SA, editors. Important advances in oncology. Philadelphia: JB Lippincott, 1990:43-64.
6. Gore M, Mainwaring P, A'Hern R, MacFarlane V, Slevin M, Harper P et al. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. J Clin Oncol 1998;16:2426-34.
7. Vriesendorp R, Aalders JG, Sleijfer DT, Pastmus PE, Willemse PH, Bouma J et al. Effective high-dose chemotherapy with autologous bone marrow infusion in resistant ovarian cancer. Gynecol Oncol 1984;17:271-6.
8. Christian MC, Trimble EL. Salvage chemotherapy for epithelial ovarian carcinoma. Gynecol Oncol 1994;55(Suppl):143-50.
9. Stiff PJ, Bayer R, Kerger C, Potkul RK, Malhatra D, Peace DJ et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutive treated patients. J Clin Oncol 1997;5:1309-17.
10. Janssen WE. Peripheral blood and bone marrow hematopoietic stem cells: are they the same? Semin Oncol 1993;20(Suppl 6):19-27.
11. Curè H, Battista C, Guastalla J, Fabbro M, Tubiana-Mathieu N, Borgeois H et al. Phase II randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with responsive low-burden advanced ovarian cancer (AOC): preliminary results of a GINECO/FNCLCC/SFGM-TC study. Proc Am Soc Clin Oncol 2001:815a.
12. Salerno MG, Ferrandina G, Greggi S, Pierelli L, Menichella G, Leone G et al. High-dose chemotherapy as a consolidation approach in advanced ovarian cancer: long-term results. Bone Marrow Transpl 2001;27:1017-25.
13. Pierelli L, Perillo A, Greggi S, Salerno G, Benedetti-Panici P, Menichella G et al. Erythroppietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison. J Clin Oncol 1999;17:1288-95.
14. Guillaume T, Rubinstein DB, Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 1998;92:1471-90.
15. Pierelli L, Perillo A, Ferrandina G, Salerno G, Rutella S, Fattorossi A et al. The role of growth factor administration and T-cell recovery after peripheral blood progenitor cell transplantation in the treatment of solid tumors: results from a randomized comparison of G-CSF and GM-CSF. Transfusion 2001;41:1577-85.
16. Perillo A, Pierelli L, Battaglia A, Salerno MG, Rutella S, Cortesi E et al. Administration of low-dose interleukin-2 plus G-CSF/EPO early after autologous PBSC transplantation: effects on immune recovery and NK activity in a prospective study in women with breast and ovarian cancer. Bone Marrow Transpl 2002, submitted.
17. Gilboa E, Nair SK, Lyerly HK. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother 1998;46:82-7.
18. Young JW, Koulova L, Soergel SA, Clark EA, Steinman RM, Dupont B. The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4-T lymphocytes by human blood dendritic cells in vitro. J Clin Invest 1992;90:229-37.
19. Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes H et al. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol 1999;163:1037-44.
20. Henderson RA, Nimgaonkar MT, Watkins SC, Robbins PD, Ball ED, Finn OJ. Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1). Cancer Res 1996;56:3763-70.
21. Szabolcs P, Moore MAS, Young JW. Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-α. J Immunol 1995;154:5851-61.
22. Strunk D, Rappersberger K, Egger C, Strobl H, Kromer E, Elbe A et al. Generation of human dendritic cells/Langerhans cells from circulating CD34+ hematopoietic progenitor cells. Blood 1996;87:1292-302.
23. Caux C, Vanbervliet B, Massacrier C, Dezutter Dambuyant C, de Saint Vis B, Jacquet C et al. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF + TNF-α. J Exp Med 1996;184:695-706.
24. Caux C, Dezutter Dambuyant C, Schmitt D, Banchereau J. GM-CSF and TNF-α cooperate in the generation of dendritic Langherans cells. Nature 1992;360:258-61.
25. Young JW, Szabolcs P, Moore MA. Identification of dendritic cell colony-forming units among normal human CD34+ bone marrow progenitors that are expanded by c-kit ligand and yield pure dendritic cell colonies in the presence of granulocyte/macrophage colony-stimulating factor and tumor necrosis factor α. J Exp Med 1995:1111-9.
26. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Cook KY et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
27. Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995;181:2109-17.
28. Ioannides CG, Fisk B, Jerome KR, Irimura T, Wharton JT, Finn OJ. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 1993;151:3693-703.
29. Yamada A, Kawano K, Harashima N, Niiya F, Nagai K, Kobayashi T et al. Study of HLA class I restriction and the directed antigens of cytotoxic T lymphocytes at the tumor sites of ovarian cancer. Cancer Immunol Immunother 1999;48:147-52.
30. Kolb HJ, Schattemberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995;86:2041-50.
31. Morecki S, Yacovlev E, Diab A, Slavin S. Allogeneic cell therapy for a murine mammary carcinoma. Cancer Res 1998;58:3891-5.
32. Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gachter A, Knapp R et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996;88:1501-8.
33. Ueno N, Rondon G, Mirza NQ, Geisler DK, Anderlini P, Giralt SA et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor risk patients with metastatic breast cancer. J Clin Oncol 1998;16:986-93.
34. Bay JO, Choufi B, Pomel C, Dauplat J, Durando X, Tournilhac O et al. Potential allogeneic graft-versus-tumor effect in a patient with ovarian cancer. Bone Marrow Transpl 2000;25:681-2.
35. Giralt S, Khouri I, Champlin R. Non myeloablative "mini transplants". Cancer Treat Res 1999;101:97-108.
36. Khouri IF, Keating M, Korbling M, Prsepiorka D, Anderlini P, O'Brien S et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell tranplantation as treatment for lymphoid malignancies. J Clin Oncol 1998;8:2817-24.
37. Hesdorffer C, Ayello J, Ward M, Kaubisch A, Vahdat L, Balmaceda C et al. Phase I trial of retroviral-mediated gene transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 1998;16:165-72.
38. Dunbar CE, Cottler-Fox M, O'Shaughnessy JA, Doren S, Carter C, Berenson P et al. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995;85:3048-57.
39. Lutzko C, Kruth S, Abrams-Ogg AC, Lau K, Li L, Clark BR et al. Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine α-L-ialuronidase deficiency. Blood 1999;93:1895-905.
40. 13 in vitro. Prog Clin Biol Res 1985;184:39-56.
41. Haylock DN, To LB, Dowse TL, Juttner CA, Simmons PJ. Ex vivo expansion and maturation of peripheral blood CD34+ cells into the myeloid lineage. Blood 1992;80:1405-12.
42. Briddel RA, Kern BP, Zilm KL, Stoney GB, McNiece IK. Purification of CD34+ cells is essential for optimal ex vivo expansion of umbilical cord blood cells. J Hematother 1997;6:145-50.
43. McNiece I, Jones R, Bearman S, Cagnoni P, Nieto Y, Franklin W et al. Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery in breast cancer patients following high-dose chemotherapy. Blood 2000;36:3001-7.
44. Paquette RL, Dergham T, Karpf E, Wang HJ, Slamon DJ, Souza L et al. Ex vivo expanded unselected peripheral blood: progenitor cells reduce post-transplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer. Blood 2000;96:2385-90.
45. Shpall EJ, Quinones R, Jones R, Bearman SI, Cagnoni P, Giller R et al. Transplantation of adult and pediatric cancer patients with cord blood progenitors expanded ex vivo. Blood 1999;94(Suppl 1):712a.
46. Rizzieri DA, Long GD, Vredenburgh JJ, Gasparetto C, Morris A, Stenzel TT et al. Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen. Blood 2001;98:3486-8.
47. Rocha V, Wagner JE, Sobocinski KA, Klein JP, Zhang MJ, Horowitz M et al. Graft versus host in children who have received a cord-blood or bone marrow transplant from HLA-identical sibling. N Engl J Med 2000;342:1846-54.